Riken Corporation

Sysmex Corporation

The Jikei University

Takehisa Matsumoto

Soichi Kojima

Takashi Saito

Mikako Shirouzu

Tomokazu Matsuura

Daisuke Takaya

Toshitada Takemori

Chiemi Tsumagari

Kozo Suto

Ikuyo Inoue

Mitsuko Hara

Takahiro Masaki

Masahiro Miura

Disclosed is an isolated monoclonal antibody against a human Transforming Growth Factor-&#x3b2; (TGF-&#x3b2;) Latency Associated Protein (LAP) degradate, the isolated monoclonal antibody being capable of recognizing an integrin binding site in the human TGF-&#x3b2; LAP degradate.

Antibody against human TGF-&#x3b2; LAP degradate, and use thereof

An object is to provide a compound capable of inhibiting activation of TGF-&#x3b2; receptors due to HCV, and a screening method for the compound. It has been found that a HCV-derived NS3 protease binds to type I TGF-&#x3b2; receptor, and this binding results in activation of TGF-&#x3b2; receptors. Moreover, binding sites between the NS3 protease and type I TGF-&#x3b2; receptor were identified, and it has been found that antibodies recognizing these binding sites inhibit activation of TGF-&#x3b2; receptors due to NS3 protease. Furthermore, it has been also found that screening for a compound capable of inhibiting activation of TGF-&#x3b2; receptors can be performed by using the inhibition of the binding between NS3 protease and type I TGF-&#x3b2; receptor or the like as an index.

Compounds having activity of suppressing activation of TGF-&#x3b2; receptor, method for screening of the compounds, and composition for preventing or treating disease caused by hepatitis C virus

Growing community of inventors

Wako, Japan

Takehisa Matsumoto